Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Neoplasms

Treatments: Drug: AZD4877

Study type: Interventional

Funder types: Industry

Identifiers

NCT00389389

D2782C00001

Details and patient eligibility

About

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experiences by patients that receive AZD4877 on a weekly basis

Enrollment: 75 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced solid tumors for which standard treatment doesn't exist or is no longer effective.
• Relatively good overall health other than your cancer.

Exclusion criteria

• Poor bone marrow function (not producing enough blood cells).
• Serious heart conditions.
• Poor liver or kidney function.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)